<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Key opportunities in the insulin delivery devices market include advancements in technology leading to user-friendly, minimally invasive, and integrated solutions. Growing adoption of connected devices, such as CGM and smart insulin pens, enhances management, especially for older adults. Expanding in wearable and bionic systems aligns with demand.<div style="float:right;padding:0 0 15px 20px;margin:15px 0 20px 20px;width:300px">
 Insulin Delivery Devices Market
 <figure>
 <img src="https://ml.globenewswire.com/Resource/Download/04628536-a6f6-43ab-b05f-3d9c94e38492" title="Insulin Delivery Devices Market" alt="Insulin Delivery Devices Market" />
 <figcaption>Insulin Delivery Devices Market</figcaption>
 </figure>
</div>Dublin, May 20, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/reports/3989899/insulin-delivery-devices-market-size-share-and?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=6mh5s4&amp;utm_campaign=2257617+-+Insulin+Delivery+Devices+Market+Analysis+and+Growth+Forecasts+Report+2026-2033+-+Uncover+New+Revenue+Streams+and+Guide+Strategic+Business+Decisions&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="Insulin Delivery Devices Market Size, Share &amp; Trends Analysis Report by Product, End Use, Region, and Growth Forecasts, 2026-2033">"Insulin Delivery Devices Market Size, Share &amp; Trends Analysis Report by Product, End Use, Region, and Growth Forecasts, 2026-2033"</a> report has been added to ResearchAndMarkets.com's offering. The global insulin delivery devices market size was estimated at USD 19.3 billion in 2025 and is expected to reach USD 35.2 billion by 2033, growing at a CAGR of 7.8% from 2026 to 2033. The growth is largely attributed to the rising global prevalence of diabetes, which has heightened the demand for advanced and user-friendly solutions for diabetes management. <img alt="" height="400" src="//www.researchandmarkets.com/content-images/2507/2507149/1/insulin-delivery-devices-market.png" width="600" /> Technological advancements play a crucial role in the market growth, with the development of devices that are more effective, less invasive, and tailored to meet patients' individual needs. Furthermore, integrating digital technology with insulin delivery devices is expected to boost market growth. This includes the rise of Continuous Glucose Monitoring (CGM) systems that work in tandem with insulin delivery devices to provide real-time glucose monitoring and automated insulin adjustments. Technological advancements in diabetes management have significantly transformed insulin delivery methods, evolving from traditional injections to more advanced, minimally invasive techniques. Initially, insulin administration faced challenges in maintaining consistent blood glucose levels. However, the advent of insulin pens facilitated easier self-administration, reducing discomfort. The development of insulin pumps allowed for continuous insulin infusion, enhancing glucose control. A pivotal advancement was the introduction of Continuous Glucose Monitoring (CGM) devices, providing real-time glucose data, essential for informed decision-making. This set the stage for Artificial Pancreas Systems (APS), which integrate CGM data with insulin pumps for automated delivery, closely mimicking natural pancreatic function. Bionic technology, blending biological and artificial processes, has been instrumental in advancing insulin delivery. It underpins devices such as APS, utilizing algorithms, sensors, and automated pumps for precise blood sugar regulation, minimizing manual intervention. These innovations offer tailored, user-friendly solutions, notably improving patient outcomes. Modern insulin pumps, equipped with CGM integration, predictive algorithms, and smartphone connectivity, exemplify significant progress in device functionality, offering accurate and adaptable insulin management. These features not only mitigate risks associated with blood glucose extremes but also empower users with finer control over their insulin dosing, responding dynamically to glucose level changes. The increasing adoption of connected diabetes management solutions is transforming the way insulin therapy is monitored and administered, with a strong focus on improving patient adherence and clinical outcomes. For instance, in December 2024, a study published by MDPI highlighted that the use of smart insulin pens integrated with continuous glucose monitoring (CGM) in pregnant women with type 1 diabetes, demonstrating improved glycemic control and increased time-in-range without severe hypoglycemia. The system enabled automatic tracking of insulin dose timing and quantity, along with real-time data sharing through a connected mobile application. This development highlights the growing role of connected insulin pen technologies in enhancing adherence and optimizing diabetes management outcomes. Furthermore, the industry is witnessing a shift towards wearable devices, such as insulin pumps and insulin patch pumps, which offer continuous insulin infusion in a convenient and discreet manner. For instance, in January 2024, PharmaSens, a Switzerland-based company specializing in medical devices, has recently applied for FDA approval in the United States for its 'niia essential' insulin patch pump system. This application represents a pivotal step for PharmaSens in the evolution of insulin pump technologies. Furthermore, the company achieved ISO 13485 certification in November 2023, encompassing the design, development, manufacturing, and distribution of insulin infusion pumps and their accessories. PharmaSens has positioned its product as focused on patient needs and ease of use. Furthermore, in January 2024, Embecta Corp. declared that it had submitted a 510(k) premarket application to the U.S. Food and Drug Administration (FDA) for its unique disposable insulin delivery system. The development of smart insulin pens, which can track and share dosage data, represents another significant trend, as does the progression towards bionic and artificial pancreas systems that more closely mimic the natural insulin delivery of a healthy pancreas. For instance, in July 2025, Byram Healthcare highlighted advancements in diabetes technology, noting that automated insulin delivery (AID) systems such as patch pumps and integrated devices significantly improved glycemic control, with clinical studies showing reductions in HbA1c levels and increased time-in-range. These systems combine insulin delivery with real-time glucose monitoring and smartphone connectivity, enhancing data tracking and patient management. This development reflects the broader trend toward connected, intelligent diabetes care solutions that mimic natural pancreatic function. The rising geriatric population is fueling the industry. These devices, such as insulin pens, pumps, and smart insulin devices, cater specifically to the needs of older adults by simplifying the insulin administration process, which can be particularly challenging due to age-related factors such as reduced vision, skill, and cognitive function. The ease of use, dosing accuracy, and the ability to integrate with digital health platforms for monitoring and reminders ensure better adherence to treatment regimens, thereby improving glycemic control &amp; reducing the risk of complications. Given the increasing prevalence of diabetes among older adults globally, the growth potential within this demographic is substantial. Why should you buy this report? <ul><li>Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.</li><li>Competitive Landscape: Explore the market presence of key players.</li><li>Future Trends: Discover the pivotal trends and drivers shaping the future of the market.</li><li>Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.</li></ul> Key Attributes: <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Report Attribute</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">Details</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">No. of Pages</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">150</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Forecast Period</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">2025 - 2033</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Estimated Market Value (USD) in 2025</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">$19.3 Billion</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Forecasted Market Value (USD) by 2033</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">$35.2 Billion</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Compound Annual Growth Rate</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">7.8%</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; ">Regions Covered</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">Global</td></tr></table> Companies Featured <ul><li>Novo Nordisk A/S</li><li>Sanofi</li><li>Eli Lilly and Company</li><li>Ypsomed AG</li><li>Medtronic</li><li>Insulet Corporation</li><li>B. Braun SE</li><li>Owen Mumford Ltd.</li><li>Tandem Diabetes Care, Inc.</li><li>BD (Becton, Dickinson and Company)</li></ul> Global Insulin Delivery Devices Market Report Segmentation Product Outlook (Revenue, USD Million, 2021-2033) <ul><li>Insulin Pens</li><li>Reusable Insulin Pens</li><li>Disposable Insulin Pens</li><li>Insulin Pumps</li><li>Tubed Pumps</li><li>Reusable Device/Components</li><li>Consumables</li><li>Tubeless Insulin Pumps</li><li>Reusable Device/Components</li><li>Consumables</li><li>Insulin Pen Needles</li><li>Standard Pen Needles</li><li>Safety Pen Needles</li><li>Insulin Syringes</li><li>Others</li></ul> End Use Outlook (Revenue, USD Million, 2021-2033) <ul><li>Hospitals &amp; Clinics</li><li>Homecare</li><li>Others</li></ul> Regional Outlook (Revenue, USD Million, 2021-2033) <ul><li>North America</li><li>U.S.</li><li>Canada</li><li>Mexico</li><li>Europe</li><li>UK</li><li>Germany</li><li>France</li><li>Italy</li><li>Spain</li><li>Denmark</li><li>Sweden</li><li>Norway</li><li>Asia Pacific</li><li>Japan</li><li>China</li><li>India</li><li>Australia</li><li>Thailand</li><li>South Korea</li><li>Latin America</li><li>Brazil</li><li>Argentina</li><li>Middle East &amp; Africa</li><li>South Africa</li><li>Saudi Arabia</li><li>UAE</li><li>Kuwait</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/3989899/insulin-delivery-devices-market-size-share-and?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=6mh5s4&amp;utm_campaign=2257617+-+Insulin+Delivery+Devices+Market+Analysis+and+Growth+Forecasts+Report+2026-2033+-+Uncover+New+Revenue+Streams+and+Guide+Strategic+Business+Decisions&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/tbil93</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. 
 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://ml.globenewswire.com/Resource/Download/04628536-a6f6-43ab-b05f-3d9c94e38492" title="Insulin Delivery Devices Market" rel="nofollow">Insulin Delivery Devices Market</a>
 </li>
 </ul>
<pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/ZmQ0NjA0ZWUtMmQwNi00OThjLWJmMWUtZmI2MDBlNzdhZDY0LTEwMjY3MzctMjAyNi0wNS0yMC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Insulin Delivery Devices Market Analysis and Growth Forecasts Report 2026-2033 - Uncover New Revenue Streams and Guide Strategic Business Decisions

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn